<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05059587</url>
  </required_header>
  <id_info>
    <org_study_id>MT14-KR20GBL309</org_study_id>
    <nct_id>NCT05059587</nct_id>
  </id_info>
  <brief_title>A Phase III Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medytox Korea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate the efficacy and safety of MBA-P01 compared to BOTOX in&#xD;
      treatment of glabellar lines.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 27, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving at least a 2-grade improvement from baseline on the facial wrinkle scale of GL at maximum frown at Week 4.</measure>
    <time_frame>Week 4</time_frame>
    <description>The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-rated improvement rate of glabellar lines at maximum frown</measure>
    <time_frame>Week 8, 12, 16</time_frame>
    <description>The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant-rated improvement rate of glabellar lines at maximum frown</measure>
    <time_frame>Week 4, 8, 12, 16</time_frame>
    <description>The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-rated improvement rate of glabellar lines at rest</measure>
    <time_frame>Week 4, 8, 12, 16</time_frame>
    <description>The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant-rated improvement rate of glabellar lines at rest</measure>
    <time_frame>Week 4, 8, 12, 16</time_frame>
    <description>The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Independent photo evaluator-rated improvement rate of glabellar lines at frown</measure>
    <time_frame>Week 4, 8, 12, 16</time_frame>
    <description>The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Independent photo evaluator-rated improvement rate of glabellar lines at rest</measure>
    <time_frame>Week 4, 8, 12, 16</time_frame>
    <description>The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant-rated satisfaction after treatment</measure>
    <time_frame>Week 4, 8, 12, 16</time_frame>
    <description>Participant evaluate the level of satisfaction by 7-grade score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Glabellar Frown Lines</condition>
  <arm_group>
    <arm_group_label>MBA-P01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBA-P01 will be injected into the GL: initial double-blind treatment on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOTOX®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BOTOX® will be injected into the GL: initial double-blind treatment on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBA-P01</intervention_name>
    <description>MBA-P01 will be injected into the Glabellar line.</description>
    <arm_group_label>MBA-P01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTOX</intervention_name>
    <description>Botox will be injected into the Glabellar line.</description>
    <arm_group_label>BOTOX®</arm_group_label>
    <other_name>OnabotulinumtoxinA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged between 20 and 65&#xD;
&#xD;
          -  Patients attaining ≥grade 2 (moderate) in the investigator's rating of the severity of&#xD;
             glabella lines at maximum frown&#xD;
&#xD;
          -  Patients who can comply with the study procedures and visit schedule&#xD;
&#xD;
          -  Patients who voluntarily sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with medical conditions who may be at greater risk due to the administration&#xD;
             of the investigational drugs (e.g.. diseases that may affect the neuromuscular action&#xD;
             including Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis and&#xD;
             motor neuropathy)&#xD;
&#xD;
          -  Patients with the history of facial nerve paralysis or the symptoms of eyelid ptosis&#xD;
&#xD;
          -  Patients who have received other procedures which may affect glabellar lines within 6&#xD;
             months&#xD;
&#xD;
          -  Patients who were injected with botulinum toxin within the past 6 months&#xD;
&#xD;
          -  Patients with allergy or hypersensitivity to the investigational drugs or their&#xD;
             components&#xD;
&#xD;
          -  Patients who have bleeding tendency or taking anti-coagulant&#xD;
&#xD;
          -  Female subjects who are pregnant or lactating. Female subjects of childbearing age who&#xD;
             have a plan to get pregnant during the study period, or do not use available&#xD;
             contraceptive methods (Women of childbearing age should have negative urine pregnancy&#xD;
             test results at baseline visit (0 week) prior to the first injection.)&#xD;
&#xD;
          -  Patients with skin disorders or infection at the injection site&#xD;
&#xD;
          -  Patients who are participating in other clinical trials or have participated in other&#xD;
             clinical trials 30 days before screening&#xD;
&#xD;
          -  Patients who are unable to communicate or follow the instructions&#xD;
&#xD;
          -  Patients who are not eligible for this study based on the judgment of an investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chung-Ang Univ. Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Dongjak-gu</state>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BeomJoon Kim</last_name>
      <phone>02-6299-1525</phone>
      <email>beomjoon74@gmail.com</email>
    </contact>
    <investigator>
      <last_name>BeomJoon Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

